Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics Inc (NQ: PLRX )

15.01 -0.93 (-5.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics Inc

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Gainers Jeffs' Brands Ltd (NASDAQ: JFBR) rose 76.5% to $2.70 in pre-market trading after jumping 19% on Friday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders will want to watch for Monday! 
Via InvestorPlace
Pliant Therapeutics Stock Surges After Positive Data From Lead Program In Scarred Lung Disorder
Pliant Therapeutics Inc (NASDAQ: PLRX) has announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic... 
Via Benzinga
Where Pliant Therapeutics Stands With Analysts
Analysts have provided the following ratings for Pliant Therapeutics (NASDAQ:PLRX) within the last quarter: 
Via Benzinga
Expert Ratings for Pliant Therapeutics
  Within the last quarter, Pliant Therapeutics (NASDAQ:PLRX) has observed the following analyst ratings: 
Via Benzinga
Salesforce, Tesla And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
3 Soaring Biotech Stocks That Could Climb Much Higher
These drugmakers have bucked the overall market's downward trend this year and expectations are still high. 
Via The Motley Fool
Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Pliant Therapeutics Inc. (NASDAQ: PLRX) Climbs to New 52-Week High
Via Investor Brand Network
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
Upgrades 
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector. 
Via InvestorPlace
Pliant Therapeutics Secures FDA Fast Track Status For Liver Disease Drug
Pliant Therapeutics (NASDAQ: PLRX) received Fast Track designation for its lead asset PLN-74809 from the U.S. Food and Drug Administration (FDA) for the potential treatment of primary sclerosing... 
Via Benzinga
4 Analysts Have This to Say About Pliant Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Pliant Therapeutics (NASDAQ:PLRX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share. 
Via Benzinga
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Short Volatility Alert: Pliant Therapeutics, Inc.
On Monday, shares of Pliant Therapeutics, Inc. (NASDAQ: PLRX) experienced volatile short activity. After the activity, the stock price went up +159.01% to $23.00. The overall sentiment for PLRX has... 
Via Benzinga
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.